Product Code: GVR-2-68038-339-3
Clinical Decision Support Systems Market Growth & Trends:
The global clinical decision support systems market size is anticipated to reach USD 10.71 billion by 2030 and is projected to grow at a CAGR of 10.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government initiatives aimed at promoting the adoption and integration of Clinical Decision Support Systems (CDSS) are expected to drive market growth by incentivizing hospitals and healthcare organizations to deploy such solutions. For example, in April 2023, the U.S. Department of Health and Human Services (HHS) revised certification program rules to encourage greater utilization of clinical decision support tools. Furthermore, advancements in AI and cloud-based CDSS technologies are projected to accelerate market expansion. The implementation of cloud-based computing to enhance CDSS platforms and database management is also anticipated to positively influence market growth in the forecast period.
During the COVID-19 pandemic, various government and community organizations initiated efforts to bolster the healthcare infrastructure. These initiatives ranged from setting up frontline clinics by state authorities to mobilizing volunteer panels of medical professionals and deploying private telemedicine platforms. Clinical Decision Support Systems (CDSS) proved indispensable during this crisis, assisting physicians in making informed decisions at the point of care.
Consequently, market participants capitalized on this opportunity to address challenges and support frontline healthcare providers. For example, in May 2022, epocrates, a subsidiary of athenahealth, Inc., enhanced its clinical decision support tools to better manage the challenges posed by the COVID-19 pandemic.
Furthermore, several companies are actively implementing strategies to enhance their clinical decision support systems (CDSS) offerings, consolidating their position in the market. For example, in February 2024, Elsevier Health collaborated with OpenEvidence, a prominent provider of AI solutions customized for the medical domain, to launch ClinicalKey AI in the U.S. This collaboration involved integrating advanced medical content with generative artificial intelligence (AI) to assist clinicians in patient-care interactions.
Clinical Decision Support Systems Market Report Highlights:
- Based on product, the standalone CDSS segment led the market with the largest revenue share of 30.85% in 2023, owing to its low cost. The segment is estimated to hold approximately 31.0% of the overall market by 2030
- Based on application, the drug allergy alerts segment led the market with the largest revenue share of 25.83% in 2023, owing to the rising burden of allergies
- Based on delivery mode, the on-premises segment held the market with the largest revenue share of 42.35% in 2023, owing to its high adoption rate by healthcare organizations
- Based on component, the services segment led the market with the largest revenue share of 42.49% in 2023, owing to high frequency of updating software and other maintenance services
- North America dominated the market with the revenue share of 43.76% in 2023, due to strong presence of market player and increasing government initiatives to promote efficient usage of clinical decision support tools
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Application
- 1.1.3. Delivery Mode
- 1.1.4. Component
- 1.1.5. Regional scope
- 1.1.6. Estimates and forecast timeline.
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Approach 1: Commodity flow approach
- 1.6.3. Volume price analysis (Model 2)
- 1.6.4. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Clinical Decision Support Systems Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Clinical Decision Support Systems Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic Landscape
- 3.4. COVID-19 Impact
Chapter 4. Clinical Decision Support Systems Market: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Clinical Decision Support Systems Market by Product Outlook
- 4.4. Standalone CDSS
- 4.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 4.5. Integrated CPOE with CDSS
- 4.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 4.6. Integrated EHR with CDSS
- 4.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 4.7. Integrated CDSS with CPOE and HER
- 4.7.1. Market estimates and forecast, 2018 to 2030 (USD Million)
Chapter 5. Clinical Decision Support Systems Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Clinical Decision Support Systems Market, by Application Outlook
- 5.4. Drug-Drug Interactions
- 5.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 5.5. Drug Allergy Alerts
- 5.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 5.6. Clinical Reminders
- 5.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 5.7. Clinical Guidelines
- 5.7.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 5.8. Drug Dosing Support
- 5.8.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 5.9. Others
- 5.9.1. Market estimates and forecast, 2018 to 2030 (USD Million)
Chapter 6. Clinical Decision Support Systems Market: Delivery Mode Estimates & Trend Analysis
- 6.1. Delivery Modes Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Clinical Decision Support Systems Market, by Delivery Modes Outlook
- 6.4. Web-Based Systems
- 6.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 6.5. Cloud-Based Systems
- 6.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 6.6. On-Premise Systems
- 6.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)
Chapter 7. Clinical Decision Support Systems Market: Component Estimates & Trend Analysis
- 7.1. Component Market Share, 2023 & 2030
- 7.2. Segment Dashboard
- 7.3. Global Clinical Decision Support Systems Market, by Component Outlook
- 7.4. Hardware
- 7.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 7.5. Software
- 7.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
- 7.6. Services
- 7.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)
Chapter 8. Clinical Decision Support Systems Market: Regional Estimates & Trend Analysis, By Type, By Application, By Delivery Mode, By Component
- 8.1. Regional Market Share Analysis, 2023 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
- 8.5. North America
- 8.5.1. U.S.
- 8.5.1.1. Key Country Dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.5.2. Canada
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6. Europe
- 8.6.1. UK
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.2. Germany
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.3. France
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Regulatory framework/ reimbursement structure
- 8.6.3.3. Competitive scenario
- 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.4. Italy
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Regulatory framework/ reimbursement structure
- 8.6.4.3. Competitive scenario
- 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.5. Spain
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Regulatory framework/ reimbursement structure
- 8.6.5.3. Competitive scenario
- 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.6. Norway
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Regulatory framework/ reimbursement structure
- 8.6.6.3. Competitive scenario
- 8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.7. Sweden
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Regulatory framework/ reimbursement structure
- 8.6.7.3. Competitive scenario
- 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.6.8. Denmark
- 8.6.8.1. Key country dynamics
- 8.6.8.2. Regulatory framework/ reimbursement structure
- 8.6.8.3. Competitive scenario
- 8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7. Asia Pacific
- 8.7.1. Japan
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. Japan market estimates and forecasts,, 2018 to 2030 (USD Million)
- 8.7.2. China
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.3. India
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.4. Australia
- 8.7.4.1. Key Country Dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.7.5. South Korea
- 8.7.5.1. Key country dynamics
- 8.7.5.2. Regulatory framework/ reimbursement structure
- 8.7.5.3. Competitive scenario
- 8.7.5.4. South Korea market estimates and forecasts,, 2018 to 2030 (USD Million)
- 8.7.6. Singapore
- 8.7.6.1. Key country dynamics
- 8.7.6.2. Regulatory framework/ reimbursement structure
- 8.7.6.3. Competitive scenario
- 8.7.6.4. Singapore market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.8. Latin America
- 8.8.1. Brazil
- 8.8.1.1. Key country dynamics
- 8.8.1.2. Regulatory framework/ reimbursement structure
- 8.8.1.3. Competitive scenario
- 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.8.2. Mexico
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Regulatory framework/ reimbursement structure
- 8.8.2.3. Competitive scenario
- 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.8.3. Argentina
- 8.8.3.1. Key country dynamics
- 8.8.3.2. Regulatory framework/ reimbursement structure
- 8.8.3.3. Competitive scenario
- 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.9. MEA
- 8.9.1. South Africa
- 8.9.1.1. Key country dynamics
- 8.9.1.2. Regulatory framework/ reimbursement structure
- 8.9.1.3. Competitive scenario
- 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.9.2. Saudi Arabia
- 8.9.2.1. Key country dynamics
- 8.9.2.2. Regulatory framework/ reimbursement structure
- 8.9.2.3. Competitive scenario
- 8.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.9.3. UAE
- 8.9.3.1. Key country dynamics
- 8.9.3.2. Regulatory framework/ reimbursement structure
- 8.9.3.3. Competitive scenario
- 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.9.4. Kuwait
- 8.9.4.1. Key country dynamics
- 8.9.4.2. Regulatory framework/ reimbursement structure
- 8.9.4.3. Competitive scenario
- 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Key company market share analysis, 2023
- 9.3.4. McKesson Corporation
- 9.3.4.1. Company overview
- 9.3.4.2. Financial performance
- 9.3.4.3. Product benchmarking
- 9.3.4.4. Strategic initiatives
- 9.3.5. Oracle (Cerner Corporation)
- 9.3.5.1. Company overview
- 9.3.5.2. Financial performance
- 9.3.5.3. Product benchmarking
- 9.3.5.4. Strategic initiatives
- 9.3.6. Siemens Healthineers GmbH
- 9.3.6.1. Company overview
- 9.3.6.2. Financial performance
- 9.3.6.3. Product benchmarking
- 9.3.6.4. Strategic initiatives
- 9.3.7. Allscripts Healthcare, LLC
- 9.3.7.1. Company overview
- 9.3.7.2. Financial performance
- 9.3.7.3. Product benchmarking
- 9.3.7.4. Strategic initiatives
- 9.3.8. athenahealth, Inc.
- 9.3.8.1. Company overview
- 9.3.8.2. Financial performance
- 9.3.8.3. Product benchmarking
- 9.3.8.4. Strategic initiatives
- 9.3.9. NextGen Healthcare Inc.
- 9.3.9.1. Company overview
- 9.3.9.2. Financial performance
- 9.3.9.3. Product benchmarking
- 9.3.9.4. Strategic initiatives
- 9.3.10. Koninklijke Philips N.V.
- 9.3.10.1. Company overview
- 9.3.10.2. Financial performance
- 9.3.10.3. Product benchmarking
- 9.3.10.4. Strategic initiatives
- 9.3.11. IBM
- 9.3.11.1. Company overview
- 9.3.11.2. Financial performance
- 9.3.11.3. Product benchmarking
- 9.3.11.4. Strategic initiatives
- 9.3.12. Agfa-Gevaert Group
- 9.3.12.1. Company overview
- 9.3.12.2. Financial performance
- 9.3.12.3. Product benchmarking
- 9.3.12.4. Strategic initiatives
- 9.3.13. Wolters Kluwer N.V.
- 9.3.13.1. Company overview
- 9.3.13.2. Financial performance
- 9.3.13.3. Product benchmarking
- 9.3.13.4. Strategic initiatives